ArticleAntimicrobial agents and chemotherapy2026
Isavuconazole for invasive mold disease in patients with hematological malignancies: a multicenter real-world study from China on efficacy, safety, and competing risks.
Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Isavuconazole is approved for invasive aspergillosis (IA) and mucormycosis, but real-world data in patients with hematological malignancies are limited. This retrospective study (2022-2025) included adult patients with hematological malignancies and proven/probable invasive mold disease (IMD) who were treated with isavuconazole for ≥72 h at two Chinese hospitals. The primary endpoint was week 6 treatment success (survival, clinical/radiological improvement, and no discontinuation due to failure/toxicity). Secondary endpoints included all-cause and IMD-attributable mortality at weeks 6 and 12 (competing risk analysis). Among 84 patients, 62 had aspergillosis (69.4% treatment success), 14 had mucormycosis (35.7%), and 8 had mixed infection (25.0%); the overall week 6 treatment success was 59.5% (50/84), with significant variation across infection types (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.